Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450

Drug Metabolism and Disposition

Volumn 33, Issue 9, 2005, Pages 1261-1267

  Chen, Chong Sheng ^a   Jounaidi, Youssef ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2B1; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; ENZYME; IFOSFAMIDE; LIVER ENZYME; PHOSPHORUS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CELL ACTIVITY; CHIRALITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG METABOLISM; ENANTIOSELECTIVITY; GLIOSARCOMA; HAMSTER; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; ISOMER; KINETICS; METABOLITE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACEMIC MIXTURE; RAT; SENSITIVITY ANALYSIS; STEADY STATE; STEREOCHEMISTRY; TUMOR CELL;

ACETALDEHYDE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; CRICETINAE; CRICETULUS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; GENE EXPRESSION; HUMANS; IFOSFAMIDE; NADPH-FERRIHEMOPROTEIN REDUCTASE; PRODRUGS; RATS; STEREOISOMERISM;

CRICETULUS GRISEUS;

EID: 23944447580     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.004788     Document Type: Article

References (40)

1. Bohnenstengel F, Eichelbaum M, Golbs E, and Kroemer HK (1997) High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes. J Chromatogr B Biomed Sci Appl 692:163-168.
2. Boos J, Welslau U, Ritter J, Blaschke G, and Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455-460.
3. Borner K, Kisro J, Bruggemann SK, Hagenah W, Peters SO, and Wagner T (2000) Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab Dispos 28:573-576.
4. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, et al. (2005) Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 11:1512-1520.
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 60:1878-1886.
6. Brueggemann SK, Schlenke P, Klich S, Deeken M, Peters SO, and Wagner T (2002) Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. Biochem Pharmacol 63:1337-1341.
7. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
8. Chang TK, Yu L, Maurel P, and Waxman DJ (1997) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
9. Chen CS, Lin JT, Goss KA, He YA, Halpert JR, and Waxman DJ (2004) Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65:1278-1285.
10. Chen L and Waxman DJ (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55:581-589.
11. Chen L and Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405-1416.
12. Corlett SA, Parker D, and Chrystyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol 39:452-455.
13. Ding S, Yao D, Burchell B, Wolf CR, and Friedberg T (1997) High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys 348:403-410.
14. Finer MH, Dull TJ, Qin L, Farson D, and Roberts MR (1994) kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83:43-50.
15. Granvil CP, Madan A, Sharkawi M, Parkinson A, and Wainer IW (1999) Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 27:533-541.
16. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, and Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899-905.
17. Huang Z and Waxman DJ (1999) High-performance liquid chromatographic- fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. Anal Biochem 273:117-125.
18. Jounaidi Y, Hecht JED, and Waxman DJ (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 58:4391-4401.
19. Jounaidi Y and Waxman DJ (2001) Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 61:4437-4444.
20. Jounaidi Y and Waxman DJ (2004) Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 64:292-303.
21. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, and Beijnen JH (2001) Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 29:967-975.
22. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
23. Lohr M, Kroger J-C, Hoffmeyer A, Freund M, Hain J, Holle A, Knofel WT, Liebe S, Nizze H, Renner M, et al. (2003) Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 1:121-131.
24. Lu H and Waxman DJ (2005) Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. Mol Pharmacol 67:212-219.
25. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735.
26. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, and Melvin WT (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1836-1842.
27. Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, Murayama N, Aoyama T, and Iida F (1996) Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. Carcinogenesis 17:1477-1481.
28. Roy P, Tretyakov O, Wright J, and Waxman DJ (1999a) Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 27:1309-1318.
29. Roy P, Yu LJ, Crespi CL, and Waxman DJ (1999b) Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles. Drug Metab Dispos 27:655-666.
30. Schmidt R, Baumann F, Knupfer H, Brauckhoff M, Horn LC, Schonfelder M, Kohler U, and Preiss R (2004) CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 90:911-916.
31. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301-355.
32. Standop J, Schneider M, Ulrich A, Buchler MW, and Pour PM (2003) Differences in immunohistochemical expression of xenobiotic-metabolizing enzymes between normal pancreas, chronic pancreatitis and pancreatic cancer. Toxicol Pathol 31:506-513.
33. Wainer IW (1993) Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing. Ann Oncol 4 (Suppl 2):7-13.
34. Wainer IW, Ducharme J, and Granvil CP (1996) The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 37:332-336.
35. Wainer IW and Granvil CP (1993) Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies. Ther Drug Monit 15:570-575.
36. Wainer IW, Granvil CP, Wang T, and Batist G (1994) Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Res 54:4393-4397.
37. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH, et al. (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-1163.
38. Williams ML and Wainer IW (1999) Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question. Curr Pharm Des 5:665-672.
39. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, and Koren G (2000) Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 68:109-117.
40. Zalupski M and Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556-566.